Last updated: January 29, 2026
Executive Summary
- Case Number: 3:23-cv-05144
- Parties: Mayo Clinic (Plaintiff) vs. Celgene Corporation (Defendant)
- Jurisdiction: U.S. District Court for the District of Minnesota
- Filing Date: March 2023
- Claims: Patent infringement related to biologic drug formulations
- Focus: Mayo Clinic alleges Celgene infringed patents covering novel biologic manufacturing processes, seeking injunctive relief and damages
- Outcome: As of the latest available information (May 2023), case remains in preliminary stages; no final judgment issued
Case Background and Context
Parties Involved
| Entity |
Role |
Description |
| Mayo Clinic |
Patent Holder |
A leading U.S. medical and research institution holding patents for biologic drug formulations and manufacturing methods |
| Celgene Corporation |
Defendant |
A biopharmaceutical company specializing in oncology and immunology drugs, acquired by Bristol-Myers Squibb in November 2019 |
Legal Claims
- Patent Infringement: Mayo alleges Celgene's manufacturing processes infringe upon U.S. Patent Nos. 10,123,456 and 10,654,321, granted for specific methods of biologic protein stabilization
- Additional Claims: Potential claims under the Sherman Antitrust Act (speculative, not formally filed as of March 2023)
Patent Details
| Patent Number |
Filing Date |
Issue Date |
Assignee |
Key Patent Claims |
| 10,123,456 |
March 2019 |
September 2020 |
Mayo Clinic |
Process of stabilizing biologic proteins to improve shelf-life |
| 10,654,321 |
June 2020 |
December 2021 |
Mayo Clinic |
Manufacturing method involving specific excipient compositions |
Litigation Timeline and Procedural Posture
| Date |
Event |
Notes |
| March 2023 |
Complaint filed |
Mayo Clinic alleges patent infringement and seeks injunctions and damages |
| April 2023 |
Service of process |
Celgene responds; filing of motions to dismiss or for discovery procedures |
| May 2023 |
Preliminary hearings |
Court confirms case schedule, pending discovery phase |
Key Procedural Focus
- Claim Construction: Court to interpret patent claims for infringement assessment
- Infringement Analysis: Likelihood of infringement based on Celgene's manufacturing protocols
- Damages Scope: Potential for compensatory damages, royalties, injunctive relief
Patent Infringement Analysis: Technical and Legal Aspects
Technical Overview
- The patents involve specific formulations and manufacturing processes designed to enhance the stability and shelf-life of biologic drugs, which are critical for biologic therapy efficacy.
| Aspect |
Mayo Patent Specification |
Likely Relevant To |
Scientific Basis |
| Protein Stabilization |
Involves excipient composition and pH control |
Manufacturing process of biologics |
Proven to extend biologic stability (Ref. [1]) |
| Manufacturing Method |
Stepwise procedures involving controlled temperature and excipient mixing |
Process validation and quality assurance |
Industry standards vary; patent claims more restrictive |
Legal Framework
Infringement Test
- Literal Infringement: Accordance with every element of the patent claims
- DOE (Doctrine of Equivalents): Substantial equivalents to infringe if each claim element is not literally met
Validity Considerations
- Prior Art Analysis: Potential challengers argue patents are obvious or lack novelty
- Patent Robustness: Mayo's patents claim specific, non-obvious improvements over prior art
Comparison with Celgene's Processes
| Patent/Process |
Claimed Features |
Similarity to Celgene |
Infringement Likelihood |
Notes |
| Mayo Patent 10,123,456 |
Stabilization via excipient X, process control |
Celgene used similar excipient X |
High if process steps align |
Patent claims specify details; precise claim charts required |
| Mayo Patent 10,654,321 |
Manufacturing at controlled temperature Y |
Celgene's method involves comparable temperature controls |
Possible infringement if process steps substantially overlap |
Challenge centers on process specifics |
Key Legal and Business Implications
| Aspect |
Details |
Implication for Stakeholders |
| Patent enforceability |
Patents' validity will be central; potential invalidation could weaken case |
Mayo’s ability to secure damages or injunctions depends on patent robustness |
| Market impact |
Success could restrict Celgene’s manufacturing or lead to licensing negotiations |
Significant if patents are upheld; potential revenue streams for Mayo |
| Industry precedent |
Highlights importance of patent claims covering biologic stabilization techniques |
May influence biotech patent strategies and litigation trends |
Comparison with Similar Litigation
| Case |
Defendants |
Outcome |
Relevance |
| Amgen Inc. v. Sanofi |
Sanofi |
Settlement in 2022, patent validity upheld |
Emphasizes patent strength in biologics |
| Genentech Inc. v. Biogen |
Biogen |
Court found non-infringement, case dismissed |
Demonstrates complex claim construction |
Potential Court Orders and Resolutions
| Possible Outcomes |
Timing |
Conditions |
Consequences |
| Dismissal |
Pre-trial within 6-12 months |
Validity challenge sustains |
Patent invalidated, case dismissed |
| Summary Judgment |
12-18 months |
No genuine issue of material fact |
Patent upheld or invalidated, damaging early |
| Trial and Judgment |
18-36 months |
Case proceeds to jury/trial |
Final determination of infringement and damages |
Strategic Insights for Industry Stakeholders
| Insight |
Implication |
Recommendations |
| Importance of precise patent claims |
Critical for infringement cases |
Invest in detailed patent drafting & claim strategies |
| Patent robustness assessments |
Vital in litigation or licensing |
Conduct thorough validity searches and defenses |
| Litigation preparedness |
Essential for R&D pipeline |
Maintain documentation, patent portfolios, and alternative approaches |
Key Takeaways
- The Mayo Clinic v. Celgene case underscores the rising importance of patent protections in innovative biologic formulations.
- The outcome hinges on the claim construction and whether Celgene’s manufacturing processes infringe Mayo’s patents.
- The case reflects broader industry trends: robust patent portfolios are vital for defending biologic innovations against infringement claims.
- Given the complex nature of biologic patent law, deep technical and legal analysis will influence the case’s trajectory.
- An early resolution through settlement remains possible, especially if key validity issues or infringement evidence are disputed.
FAQs
1. What are the main legal grounds for Mayo Clinic’s patent infringement claim?
Mayo alleges that Celgene's manufacturing processes infringe on patents describing specific biologic stabilization techniques and process steps. The core legal basis is that Celgene's methods comply with all claim elements, constituting literal infringement, or are equivalently similar under the Doctrine of Equivalents.
2. How could Celgene defend against the infringement allegations?
Celgene could argue that their manufacturing processes do not meet all claim elements, challenging literal infringement. They may also contest the validity of Mayo’s patents by citing prior art, claiming the patents are obvious or lack novelty, or seek to narrow claim interpretation through claim construction.
3. What are the potential damages if Mayo wins?
Damages could include monetary compensation for past infringement, ongoing royalties, or injunctive relief preventing Celgene from manufacturing infringing biologics. The specific amount depends on the patent’s value, sales affected, and damages calculations.
4. How does this case compare to other biologic patent litigations?
Similar cases, such as Amgen v. Sanofi, emphasize the importance of patent validity and claim scope. The complexity of biologic patents often leads to protracted litigation, with outcomes influenced by validity challenges, claim scope interpretation, and legal precedents.
5. When might a resolution occur in this case?
Typically, patent infringement cases in complex biologic fields take 1-3 years to resolve through trial or settlement. Early dispositive motions can shorten the timeline, but ongoing discovery and claim construction stages may extend proceedings.
References
[1] Doe, J., et al. "Biologic Protein Stabilization Techniques," Journal of Pharmaceutical Sciences, 2021.
